Immuneering Corporation

IMRX | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.44

-$0.04 (-0.89%)

At close: Sep 21, 2026, 4:00 PM ET

$4.50

+$0.06 (+1.35%)

Pre-market: Sep 22, 2026, 5:54 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.89%

(1D)

Rating

Updated: Sep 11, 2026

13.5

Fundamentals Weak

Market Sentiment Bearish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $161.18M

1D Range

4.39 4.55

52W Range

3.86 10.08

Valuation (TTM)

PE -4.27

PB 0.85

EV/EBITDA -0.24

Valuation (NTM)

Forward PE N/A

Forward PEG -0.35

Price Target $15.50

Cash Flow

FCF Yield -21754.3%

SBC Adj. FCF Yield -23779.7%

SBC Impact -9.3%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | -98.0%

Dil EPS 3Y | 5Y 27.0% | -60.9%

FCF 3Y | 5Y -149.3% | -99.3%

Returns

ROA -28.4%

ROE -27.1%

ROIC -32.6%

Financial Health

Net Cash

$149.9M

Current Ratio 19.47

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development effort...

Sector Healthcare

Industry Biotechnology

Employees 57

IPO Date Jul 29, 2021

Website immuneering.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$15.50

Upside

+249.10%

Buy (4)

Hold (0)

Sell (0)

Analyst Details ➞